{"schema_version":"secwatch.filing_event.v1","accession":"0001339970-25-000016","form_type":"8-K/A","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.775416+00:00","generated_at":"2026-05-17T16:12:30.390018+00:00","sec_items":["2.02","9.01","2.06"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"aTyr Pharma Phase 3 EFZO-FIT topline due mid-Sept; Q2 cash $83.2M, raised $30.7M ATM","bullets":["Completed last patient visit in Phase 3 EFZO-FIT study for pulmonary sarcoidosis; topline results expected mid-September 2025.","Interim Phase 2 data in SSc-ILD showed stable/improved mRSS in diffuse patients; no treatment-related serious adverse events.","ATYR0101 advanced to IND candidate for pulmonary fibrosis; IND filing planned in H2 2026.","Cash, equivalents and investments $83.2M at June 30, 2025; raised ~$30.7M in ATM offering after quarter-end.","R&D expenses $15.4M, G&A $4.9M for Q2 2025; cash runway sufficient for one year after Phase 3 readout."],"urls":{"canonical":"https://secwatch.observer/filing/0001339970-25-000016","json":"https://secwatch.observer/filing/0001339970-25-000016.json","markdown":"https://secwatch.observer/filing/0001339970-25-000016.md","text":"https://secwatch.observer/filing/0001339970-25-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000133997025000016/0001339970-25-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000133997025000016/atyr-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:12:30.390018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}